New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Research capsule

Vital stats: Glanbia Nutritionals' Prolibra whey protein fraction

Study claim: Prolibra retains lean muscle mass.

Published: Frestedt JL, et al. A whey-protein supplement increases fat loss and spares lean muscle in obese subjects: a randomized human clinical study. Nutr Metab 2008;5:8-14.

Abstract: This study evaluated a specialized whey fraction (Prolibra, high in leucine, bioactive peptides and milk calcium) for use as a dietary supplement to enhance weight loss. This was a randomised, double-blind, parallel-arm, 12-week study. Caloric intake was reduced by 500 calories per day. Subjects consumed Prolibra or an isocaloric ready-to-mix beverage 20 minutes before breakfast and 20 minutes before dinner. Body weight and anthropometric measurements were recorded every four weeks.

After 12 weeks, Prolibra subjects lost significantly more body fat compared to control subjects for both the completer (2.81kg vs 1.62kg) and responder (3.63kg vs 2.11kg) groups. Prolibra subjects lost significantly less lean muscle mass in the responder group (1.07kg vs 2.41kg). The ratio of fat to lean muscle loss was much larger for

Prolibra subjects for both completer (3.75kg vs 1.05kg) and responder (3.39kg vs 0.88kg) groups.

Subjects in both the control and treatment groups lost a significant amount of weight with a 500-calorie-reduced diet. Subjects taking Prolibra lost significantly more body fat and showed a greater preservation of lean muscle compared to subjects consuming the control beverage. Because subjects taking Prolibra lost 6.1 per cent of their body fat mass, and because a five per cent reduction of body fat mass has been shown to reduce the risk of obesity-related disease, the results have practical significance.

The full study is available at

Potential applications: Suitable for nutrition bars, ready-to-drink beverages, powdered beverages, fruit beverages and smoothies, dairy beverages, and snacks. Based on a daily consumption of an efficacious dose of Prolibra, the following claims may be made: helps improve body composition; helps improve lean mass to fat ratio; helps reduce body fat; helps support fat loss; aids fat loss; helps maintain already healthy levels of blood glucose; helps maintain a healthy glycaemic response; helps to feel fuller longer.

More info:
+1 608 329 2800

HMRlignanVital stats: Linnea's HMRlignan

Study claim: HMRlignan inhibits proliferation of prostate cancer cells.

Published: McCann MJ, et al. Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Mol Nutr Food Res 2008 May;52(5):567-80.

Abstract: Ecological data suggest a long-term diet high in plant material rich in biologically active compounds, such as lignans, can significantly influence the development of prostate cancer over the lifetime of an individual. The capacity of a pure mammalian lignan, enterolactone (ENL), to influence the proliferation of the LNCaP human prostate cancer-cell line was investigated as a function of cell density, metabolic activity, expression and secretion of prostate specific antigen (PSA), cell-cycle profile, and the expression of genes involved in development and progression of prostate cancer.

Treatment with a subcytotoxic concentration of ENL (60muM for 72 hours) was found to reduce cell density (57.5 per cent, SD 7.23), metabolic activity (55 per cent, SD 0.03), and secretion of PSA (48.50 per cent, SD 4.74), and induce apoptosis (8.33-fold SD 0.04) compared to untreated cells. Co-treatment with 10muM etoposide was found to increase apoptosis by 50.17 per cent (SD 0.02). Additionally, several key genes (eg, MCMs, survivin and CDKs) were beneficially regulated by ENL treatment.

The data suggest that the antiproliferative activity of ENL is a consequence of altered expression of cell cycle associated genes and provides novel molecular evidence for the antiproliferative properties of a pure lignan in prostate cancer.

Potential applications: HMRlignan, derived from Norway Spruce (Picea abies) and available exclusively from Linnea, offers a convenient, low-dose and highly bioavailable solution to supplement dietary lignans intake and boost circulating enterolactone levels. HMRlignan is standardised to contain 80,000mg/100g of lignans, and the daily dosage to raise enterolactone levels is 10-30mg.

More info:
+1 610 253 7950

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.